Identification

Name
Hydrochlorothiazide
Accession Number
DB00999  (APRD00092)
Type
Small Molecule
Groups
Approved, Vet approved
Description

A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It has been used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism. [PubChem]

Structure
Thumb
Synonyms
  • HCTZ
External IDs
NSC-53477 / SU-5879
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Hydro Tab 100mgTablet100 mgOralApotex Corporation1988-12-31Not applicableCanada
Apo Hydro Tab 25mgTablet25 mgOralApotex Corporation1975-12-31Not applicableCanada
Apo Hydro Tab 50mgTablet50 mgOralApotex Corporation1974-12-31Not applicableCanada
Diuchlor H Tab 50mgTablet50 mgOralMedic Laboratory LtÉe1964-12-311996-09-09Canada
HydrochlorothiazideTablet50 mgOralSobio Pharmaceutical Canada Inc.Not applicableNot applicableCanada
HydrochlorothiazideTablet25 mgOralSobio Pharmaceutical Canada Inc.Not applicableNot applicableCanada
HydrochlorothiazideTablet50 mgOralSanis Health Inc2011-02-08Not applicableCanada
HydrochlorothiazideTablet25 mgOralSanis Health Inc2011-02-08Not applicableCanada
Hydrochlorothiazide 100 TabTablet100 mgOralPro Doc Limitee1981-12-312009-07-23Canada
Hydrochlorothiazide 100mg TabletsTablet100 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-hydroTablet12.5 mgOralApotex Corporation2009-07-02Not applicableCanada
Ava-hydrochlorothiazideTablet12.5 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-hydrochlorothiazideTablet50 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-hydrochlorothiazideTablet25 mgOralAvanstra Inc2011-10-112014-08-21Canada
Bio-hydrochlorothiazideTablet25 mgOralBiomed Pharma2003-04-11Not applicableCanada
Bio-hydrochlorothiazideTablet50 mgOralBiomed Pharma2003-04-11Not applicableCanada
Bio-hydrochlorothiazideTablet100 mgOralBiomed PharmaNot applicableNot applicableCanada
Dom-hydrochlorothiazideTablet25 mgOralBiomed Pharma2004-02-062013-08-02Canada
Dom-hydrochlorothiazideTablet12.5 mgOralDominion Pharmacal2006-08-022007-11-02Canada
Dom-hydrochlorothiazideTablet50 mgOralBiomed Pharma2004-02-062013-08-02Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Accel-candesartan/hctzHydrochlorothiazide (12.5 mg) + Candesartan cilexetil (32 mg)TabletOralAccel Pharma Inc2017-12-27Not applicableCanada
Accel-candesartan/hctzHydrochlorothiazide (25 mg) + Candesartan cilexetil (32 mg)TabletOralAccel Pharma Inc2017-12-27Not applicableCanada
Accel-candesartan/hctzHydrochlorothiazide (12.5 mg) + Candesartan cilexetil (16 mg)TabletOralAccel Pharma Inc2017-12-27Not applicableCanada
AccureticHydrochlorothiazide (12.5 mg/1) + Quinapril Hydrochloride (20 mg/1)Tablet, film coatedOralParke Davis Div Of Pfizer Inc1999-12-28Not applicableUs
AccureticHydrochlorothiazide (12.5 mg/1) + Quinapril Hydrochloride (10 mg/1)Tablet, film coatedOralParke Davis Div Of Pfizer Inc1999-12-28Not applicableUs
AccureticHydrochlorothiazide (25 mg/1) + Quinapril Hydrochloride (20 mg/1)Tablet, film coatedOralParke Davis Div Of Pfizer Inc1999-12-28Not applicableUs
Accuretic 10/12.5 mgHydrochlorothiazide (12.5 mg) + Quinapril (10 mg)TabletOralPfizer1998-10-01Not applicableCanada
Accuretic 20/12.5 mgHydrochlorothiazide (12.5 mg) + Quinapril (20 mg)TabletOralPfizer1998-10-01Not applicableCanada
Accuretic 20/25 mgHydrochlorothiazide (25 mg) + Quinapril (20 mg)TabletOralPfizer2003-06-02Not applicableCanada
Ach-olmesartan HctzHydrochlorothiazide (12.5 mg) + Olmesartan medoxomil (20 mg)TabletOralAccord Healthcare LimitedNot applicableNot applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Imprida HCTHydrochlorothiazide (25 mg) + Amlodipine (10 mg) + Valsartan (320 mg)Tablet, film coatedOralNovartis Europharm Limited2009-10-152012-10-22Eu
Imprida HCTHydrochlorothiazide (12.5 mg) + Amlodipine (5 mg) + Valsartan (160 mg)Tablet, film coatedOralNovartis Europharm Limited2009-10-152012-10-22Eu
Imprida HCTHydrochlorothiazide (25 mg) + Amlodipine (10 mg) + Valsartan (160 mg)Tablet, film coatedOralNovartis Europharm Limited2009-10-152012-10-22Eu
Imprida HCTHydrochlorothiazide (25 mg) + Amlodipine (5 mg) + Valsartan (160 mg)Tablet, film coatedOralNovartis Europharm Limited2009-10-152012-10-22Eu
Imprida HCTHydrochlorothiazide (12.5 mg) + Amlodipine (10 mg) + Valsartan (160 mg)Tablet, film coatedOralNovartis Europharm Limited2009-10-152012-10-22Eu
Imprida HCTHydrochlorothiazide (12.5 mg) + Amlodipine (5 mg) + Valsartan (160 mg)Tablet, film coatedOralNovartis Europharm Limited2009-10-152012-10-22Eu
Imprida HCTHydrochlorothiazide (25 mg) + Amlodipine (10 mg) + Valsartan (160 mg)Tablet, film coatedOralNovartis Europharm Limited2009-10-152012-10-22Eu
Imprida HCTHydrochlorothiazide (25 mg) + Amlodipine (5 mg) + Valsartan (160 mg)Tablet, film coatedOralNovartis Europharm Limited2009-10-152012-10-22Eu
Imprida HCTHydrochlorothiazide (12.5 mg) + Amlodipine (10 mg) + Valsartan (160 mg)Tablet, film coatedOralNovartis Europharm Limited2009-10-152012-10-22Eu
Imprida HCTHydrochlorothiazide (12.5 mg) + Amlodipine (5 mg) + Valsartan (160 mg)Tablet, film coatedOralNovartis Europharm Limited2009-10-152012-10-22Eu
International/Other Brands
Dichlotride (M & H) / Esidrex (Novartis) / Esidrix / Hydrodiuril (Merck) / HydroDIURIL (Merck) / Microzide
Categories
UNII
0J48LPH2TH
CAS number
58-93-5
Weight
Average: 297.739
Monoisotopic: 296.964474846
Chemical Formula
C7H8ClN3O4S2
InChI Key
JZUFKLXOESDKRF-UHFFFAOYSA-N
InChI
InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)
IUPAC Name
6-chloro-1,1-dioxo-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1

Pharmacology

Indication

For the treatment of high blood pressure and management of edema.

Associated Conditions
Pharmacodynamics

Thiazides such as hydrochlorothiazide promote water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.

Mechanism of action

Hydrochlorothiazide, a thiazide diuretic, inhibits water reabsorption in the nephron by inhibiting the sodium-chloride symporter (SLC12A3) in the distal convoluted tubule, which is responsible for 5% of total sodium reabsorption. Normally, the sodium-chloride symporter transports sodium and chloride from the lumen into the epithelial cell lining the distal convoluted tubule. The energy for this is provided by a sodium gradient established by sodium-potassium ATPases on the basolateral membrane. Once sodium has entered the cell, it is transported out into the basolateral interstitium via the sodium-potassium ATPase, causing an increase in the osmolarity of the interstitium, thereby establishing an osmotic gradient for water reabsorption. By blocking the sodium-chloride symporter, hydrochlorothiazide effectively reduces the osmotic gradient and water reabsorption throughout the nephron.

TargetActionsOrganism
ASolute carrier family 12 member 3
inhibitor
Human
UCarbonic anhydrase 1
inhibitor
Human
UCarbonic anhydrase 2
inhibitor
Human
ACalcium-activated potassium channel subunit alpha-1
inhibitor
Human
Absorption

50-60%

Volume of distribution
Not Available
Protein binding

67.9%

Metabolism

Hydrochlorothiazide is not metabolized.

Route of elimination

Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.

Half life

5.6 and 14.8 hours

Clearance
Not Available
Toxicity

The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in the mouse and rat.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Hydrochlorothiazide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(2-benzhydryloxyethyl)diethyl-methylammonium iodideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with (2-benzhydryloxyethyl)diethyl-methylammonium iodide.Experimental
(R)-warfarinThe therapeutic efficacy of (R)-warfarin can be increased when used in combination with Hydrochlorothiazide.Experimental
(S)-WarfarinThe therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Hydrochlorothiazide.Experimental, Investigational
1alpha-Hydroxyvitamin D5The risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with 1alpha-Hydroxyvitamin D5.Investigational
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Hydrochlorothiazide.Investigational
4-hydroxycoumarinThe therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Hydrochlorothiazide.Experimental
AbediterolAbediterol may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
AcebutololHydrochlorothiazide may increase the hypotensive activities of Acebutolol.Approved, Investigational
AceclofenacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be increased when used in combination with Hydrochlorothiazide.Approved, Investigational
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational, Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Aclidinium.Approved
AgmatineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Agmatine.Experimental, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Hydrochlorothiazide.Experimental, Investigational
AlaproclateThe risk or severity of hyponatremia can be increased when Alaproclate is combined with Hydrochlorothiazide.Experimental
AlbiglutideThe therapeutic efficacy of Albiglutide can be decreased when used in combination with Hydrochlorothiazide.Approved
AlclofenacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
AlcuroniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydrochlorothiazide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Hydrochlorothiazide.Experimental, Investigational
AlfacalcidolThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Alfacalcidol.Approved, Nutraceutical
AlfentanilThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
AliskirenHydrochlorothiazide may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Hydrochlorothiazide.Approved
AlminoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydrochlorothiazide.Approved
AlphacetylmethadolThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Alphaprodine.Illicit
AlprenololHydrochlorothiazide may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmantadineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Amantadine.Approved
AmbrisentanHydrochlorothiazide may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved
AMG-222The therapeutic efficacy of AMG-222 can be decreased when used in combination with Hydrochlorothiazide.Investigational
AmifostineHydrochlorothiazide may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Hydrochlorothiazide.Approved
Aminobenzoic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Aminobenzoic acid.Approved, Experimental
AminophenazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Aminophenazone.Approved, Withdrawn
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Hydrochlorothiazide.Approved, Investigational
AmitriptylineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Amitriptyline.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Hydrochlorothiazide.Approved
AmobarbitalThe risk or severity of hypotension and orthostatic hypotension can be increased when Amobarbital is combined with Hydrochlorothiazide.Approved, Illicit
AmoxapineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Amoxapine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Hydrochlorothiazide.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Amyl Nitrite.Approved
AnagliptinThe therapeutic efficacy of Anagliptin can be decreased when used in combination with Hydrochlorothiazide.Investigational
Anisotropine MethylbromideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Antipyrine.Approved, Investigational
AntrafenineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Antrafenine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Hydrochlorothiazide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Hydrochlorothiazide.Approved
AprobarbitalThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Aprobarbital.Approved, Illicit
ArbutamineArbutamine may increase the hypokalemic activities of Hydrochlorothiazide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Hydrochlorothiazide.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydrochlorothiazide.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Hydrochlorothiazide.Approved
AtracuriumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Atropine.Approved, Vet Approved
AvanafilAvanafil may increase the antihypertensive activities of Hydrochlorothiazide.Approved
AzapropazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Azapropazone.Withdrawn
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Azilsartan medoxomil.Approved, Investigational
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Hydrochlorothiazide.Investigational
BalsalazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
BarbexacloneThe risk or severity of hypotension and orthostatic hypotension can be increased when Barbexaclone is combined with Hydrochlorothiazide.Experimental
BarbitalThe risk or severity of hypotension and orthostatic hypotension can be increased when Barbital is combined with Hydrochlorothiazide.Illicit
Barbituric acid derivativeThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Barbituric acid derivative.Experimental, Illicit
BarnidipineHydrochlorothiazide may increase the antihypertensive activities of Barnidipine.Approved
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
BecocalcidiolThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Becocalcidiol.Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Hydrochlorothiazide.Investigational
BenactyzineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilHydrochlorothiazide may increase the hypotensive activities of Benazepril.Approved, Investigational
BenazeprilatThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Benazeprilat.Experimental
BendazacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Hydrochlorothiazide.Approved
BenfluorexThe therapeutic efficacy of Benfluorex can be decreased when used in combination with Hydrochlorothiazide.Investigational, Withdrawn
BenmoxinBenmoxin may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
BenorilateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Benzatropine.Approved
BenziloneThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Benzilone.Experimental
BenzquinamideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Benzquinamide.Withdrawn
BenzydamineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Benzydamine.Approved
BepridilHydrochlorothiazide may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
BetaxololBetaxolol may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Hydrochlorothiazide.Approved
BevantololHydrochlorothiazide may increase the hypotensive activities of Bevantolol.Approved
BevoniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Bevonium.Experimental
BezitramideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bezitramide.Experimental, Illicit, Withdrawn
BietaserpineBietaserpine may increase the hypotensive activities of Hydrochlorothiazide.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
BiperidenThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Biperiden.Approved, Investigational
BisacodylThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Bisacodyl.Approved
BisoprololBisoprolol may increase the hypotensive activities of Hydrochlorothiazide.Approved
BisoxatinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Bisoxatin.Approved
BitolterolBitolterol may increase the hypokalemic activities of Hydrochlorothiazide.Withdrawn
BornaprineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Bornaprine.Experimental
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Hydrochlorothiazide.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Botulinum Toxin Type B.Approved, Investigational
BQ-123Hydrochlorothiazide may increase the hypotensive activities of BQ-123.Investigational
BretyliumHydrochlorothiazide may increase the hypotensive activities of Bretylium.Approved
BromfenacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
BrompheniramineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Brompheniramine.Approved
BuclizineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Buclizine.Approved
BudesonideBudesonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved
BufexamacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bufexamac.Approved, Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Hydrochlorothiazide.Investigational, Withdrawn
BumadizoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Hydrochlorothiazide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydrochlorothiazide.Approved, Investigational
BupranololHydrochlorothiazide may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Bupropion.Approved
ButabarbitalThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Butabarbital.Approved, Illicit
ButalbitalThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Butalbital.Approved, Illicit
ButethalThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Butethal.Approved, Illicit
ButorphanolThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Butylscopolamine.Approved, Investigational, Vet Approved
CadralazineCadralazine may increase the hypotensive activities of Hydrochlorothiazide.Experimental
CalcidiolThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Calcipotriol.Approved
CalcitriolThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Calcitriol.Approved, Nutraceutical
Calcium AcetateHydrochlorothiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved, Investigational
Calcium CarbonateHydrochlorothiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved, Investigational
Calcium ChlorideHydrochlorothiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
Calcium CitrateHydrochlorothiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
Calcium glubionateHydrochlorothiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateHydrochlorothiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateHydrochlorothiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
Calcium lactateHydrochlorothiazide may decrease the excretion rate of Calcium lactate which could result in a higher serum level.Approved, Investigational, Vet Approved
Calcium lactate gluconateHydrochlorothiazide may decrease the excretion rate of Calcium lactate gluconate which could result in a higher serum level.Experimental
Calcium levulinateHydrochlorothiazide may decrease the excretion rate of Calcium levulinate which could result in a higher serum level.Approved, Experimental
Calcium pangamateHydrochlorothiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level.Experimental
Calcium PhosphateHydrochlorothiazide may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.Approved
CamylofinThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Camylofin.Experimental
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrochlorothiazide.Approved
CandesartanHydrochlorothiazide may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of hypotension, hyperkalemia, and hypokalemia can be increased when Candesartan cilexetil is combined with Hydrochlorothiazide.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Hydrochlorothiazide.Experimental
CaptoprilThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Hydrochlorothiazide.Approved, Investigational
CarboxymethylcelluloseThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Carboxymethylcellulose.Approved, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Hydrochlorothiazide.Experimental
CarfentanilThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Carfentanil.Illicit, Investigational, Vet Approved
CarmegliptinThe therapeutic efficacy of Carmegliptin can be decreased when used in combination with Hydrochlorothiazide.Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
CarprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololHydrochlorothiazide may increase the hypotensive activities of Carteolol.Approved
CarvedilolHydrochlorothiazide may increase the hypotensive activities of Carvedilol.Approved, Investigational
Castor oilThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Castor oil.Approved, Investigational, Nutraceutical, Vet Approved
CelecoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololHydrochlorothiazide may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroprocaineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Chloroprocaine.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
ChlorprothixeneThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Hydrochlorothiazide.Approved
CholecalciferolThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Hydrochlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
CicletanineHydrochlorothiazide may increase the hypotensive activities of Cicletanine.Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Hydrochlorothiazide.Experimental
CilazaprilThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Hydrochlorothiazide.Approved, Investigational
CimicoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Cimicoxib.Investigational
CisatracuriumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Cisatracurium.Approved
CitalopramThe risk or severity of hyponatremia can be increased when Citalopram is combined with Hydrochlorothiazide.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Clevidipine.Approved, Investigational
ClidiniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Clidinium.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Hydrochlorothiazide.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Hydrochlorothiazide.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Hydrochlorothiazide.Approved
ClonixinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Clonixin.Approved
CloprednolCloprednol may increase the hypokalemic activities of Hydrochlorothiazide.Experimental
CloranololHydrochlorothiazide may increase the hypotensive activities of Cloranolol.Experimental
ClorindioneThe therapeutic efficacy of Clorindione can be increased when used in combination with Hydrochlorothiazide.Experimental
ClozapineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Clozapine.Approved
CocaineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Codeine.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Hydrochlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Hydrochlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Hydrochlorothiazide.Approved, Investigational
CorticotropinCorticotropin may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational, Vet Approved
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
CortivazolCortivazol may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Hydrochlorothiazide.Approved
CyclopentamineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cyclopentamine.Withdrawn
CyclopenthiazideHydrochlorothiazide may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclopentolateThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of granulocytopenia can be increased when Hydrochlorothiazide is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Hydrochlorothiazide.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Hydrochlorothiazide.Approved
CycrimineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Cycrimine.Approved
CymarinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cymarin.Experimental
CyproheptadineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Cyproheptadine.Approved
DanthronThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Danthron.Approved, Investigational, Withdrawn
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Hydrochlorothiazide.Approved
DapoxetineThe risk or severity of hyponatremia can be increased when Dapoxetine is combined with Hydrochlorothiazide.Investigational
DarifenacinThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Darifenacin.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
DeflazacortDeflazacort may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
DelaprilThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Delapril.Investigational
DeserpidineHydrochlorothiazide may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Hydrochlorothiazide.Approved
DesipramineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Desipramine.Approved, Investigational
DeslanosideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Deslanoside.Approved
DesonideDesonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
DesvenlafaxineThe risk or severity of hyponatremia can be increased when Desvenlafaxine is combined with Hydrochlorothiazide.Approved, Investigational
DexamethasoneDexamethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Hydrochlorothiazide.Vet Approved
DexetimideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Dexetimide.Withdrawn
DexibuprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Hydrochlorothiazide.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hydrochlorothiazide.Approved, Vet Approved
DexniguldipineHydrochlorothiazide may increase the hypotensive activities of Dexniguldipine.Experimental
DextromethorphanThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Dezocine.Approved, Investigational
DiazoxideDiazoxide may increase the hypotensive activities of Hydrochlorothiazide.Approved
DiclofenacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Diclofenamide.Approved, Investigational
DicoumarolThe therapeutic efficacy of Dicoumarol can be increased when used in combination with Hydrochlorothiazide.Approved
DicyclomineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Dicyclomine.Approved
DiethylnorspermineHydrochlorothiazide may increase the hypotensive activities of Diethylnorspermine.Investigational
DifemerineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Difemerine.Experimental
DifenpiramideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
DiflunisalThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Diflunisal.Approved, Investigational
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational, Withdrawn
DifluprednateDifluprednate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin.Approved
DihexyverineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Dihexyverine.Experimental
DihydralazineDihydralazine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
DihydrocodeineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Dihydromorphine.Experimental, Illicit
DihydrotachysterolThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Dihydrotachysterol.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
DimetindeneThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Dimetindene.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Dinutuximab.Approved, Investigational
DiphemanilThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Diphemanil.Experimental
Diphemanil MethylsulfateThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Diphemanil Methylsulfate.Approved, Vet Approved, Withdrawn
DiphenadioneThe therapeutic efficacy of Diphenadione can be increased when used in combination with Hydrochlorothiazide.Experimental
DiphenhydramineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Diphenhydramine.Approved, Investigational
DiphenidolThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Diphenidol.Approved, Investigational, Withdrawn
DiphenoxylateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Diphenoxylate.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Hydrochlorothiazide.Approved
DipyridamoleDipyridamole may increase the antihypertensive activities of Hydrochlorothiazide.Approved
DisopyramideThe therapeutic efficacy of Disopyramide can be decreased when used in combination with Hydrochlorothiazide.Approved
DobutamineDobutamine may increase the hypokalemic activities of Hydrochlorothiazide.Approved
DocusateThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Docusate.Approved
DofetilideThe risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Dofetilide.Approved, Investigational
DorzolamideDorzolamide may increase the hypotensive activities of Hydrochlorothiazide.Approved
DosulepinThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Dosulepin.Approved
DoxacuriumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Doxacurium.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Hydrochlorothiazide.Approved
DoxepinThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Doxepin.Approved, Investigational
DoxercalciferolThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Doxercalciferol.Approved
DoxofyllineDoxofylline may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
DoxylamineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Doxylamine.Approved, Vet Approved
DPDPEThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with DPDPE.Experimental
DroxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Droxicam.Withdrawn
DroxidopaDroxidopa may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
DuloxetineHydrochlorothiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DutogliptinThe therapeutic efficacy of Dutogliptin can be decreased when used in combination with Hydrochlorothiazide.Investigational
EfonidipineHydrochlorothiazide may increase the hypotensive activities of Efonidipine.Approved, Investigational
EldecalcitolThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Eldecalcitol.Investigational
ElocalcitolThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Elocalcitol.Investigational
EluxadolineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Eluxadoline.Approved, Investigational
EmeproniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Emepronium.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydrochlorothiazide.Approved
EnalaprilThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Hydrochlorothiazide.Experimental
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Hydrochlorothiazide.Experimental
EpanololHydrochlorothiazide may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Hydrochlorothiazide.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Hydrochlorothiazide.Approved
EprosartanEprosartan may increase the hypotensive activities of Hydrochlorothiazide.Approved
ErgocalciferolThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Ergocalciferol.Approved, Nutraceutical
EsatenololHydrochlorothiazide may increase the hypotensive activities of Esatenolol.Experimental
EscitalopramThe risk or severity of hyponatremia can be increased when Escitalopram is combined with Hydrochlorothiazide.Approved, Investigational
EsmololHydrochlorothiazide may increase the hypotensive activities of Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Hydrochlorothiazide.Approved, Investigational
EtafedrineEtafedrine may increase the hypokalemic activities of Hydrochlorothiazide.Approved
EtanautineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Etanautine.Experimental
EthanolThe risk or severity of hypotension and orthostatic hypotension can be increased when Ethanol is combined with Hydrochlorothiazide.Approved
EthenzamideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ethenzamide.Experimental
EthopropazineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Ethopropazine.Approved
Ethyl biscoumacetateThe therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Hydrochlorothiazide.Withdrawn
EthylmorphineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ethylmorphine.Approved, Illicit
EtodolacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoricoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etorphine.Illicit, Vet Approved
EtybenzatropineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Etybenzatropine.Experimental
EvogliptinThe therapeutic efficacy of Evogliptin can be decreased when used in combination with Hydrochlorothiazide.Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
FelbinacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Felbinac.Experimental
FelodipineHydrochlorothiazide may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Hydrochlorothiazide.Approved
FenoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
FenpiveriniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Fenpiverinium.Experimental
FentanylThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Feprazone.Experimental
Ferulic acidHydrochlorothiazide may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Fesoterodine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Hydrochlorothiazide.Approved, Investigational
FirocoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Firocoxib.Experimental, Vet Approved
FlavoxateThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Flavoxate.Approved
FloctafenineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FlucloroloneFluclorolone may increase the hypokalemic activities of Hydrochlorothiazide.Experimental
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
FluindioneThe therapeutic efficacy of Fluindione can be increased when used in combination with Hydrochlorothiazide.Approved, Investigational
FlumethasoneFlumethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
FlunixinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
FluocortinFluocortin may increase the hypokalemic activities of Hydrochlorothiazide.Experimental
FluocortoloneFluocortolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
FluoxetineThe risk or severity of hyponatremia can be increased when Fluoxetine is combined with Hydrochlorothiazide.Approved, Vet Approved
FlupentixolThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Flupentixol.Approved, Investigational, Withdrawn
FluperoloneFluperolone may increase the hypokalemic activities of Hydrochlorothiazide.Experimental
FluprednideneFluprednidene may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Hydrochlorothiazide.Approved
FlurbiprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluticasoneFluticasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Experimental, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
Fluticasone propionateFluticasone propionate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
FluvoxamineThe risk or severity of hyponatremia can be increased when Fluvoxamine is combined with Hydrochlorothiazide.Approved, Investigational
FormocortalFormocortal may increase the hypokalemic activities of Hydrochlorothiazide.Experimental
FormoterolFormoterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
FosinoprilThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Fosinopril.Approved
FosinoprilatThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Fosinoprilat.Experimental
FostamatinibFostamatinib may increase the antihypertensive activities of Hydrochlorothiazide.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Hydrochlorothiazide.Approved, Vet Approved
GallamineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Gallamine.Experimental
Gallamine TriethiodideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Gallamine Triethiodide.Approved
Gantacurium ChlorideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Gantacurium Chloride.Investigational
GemigliptinThe therapeutic efficacy of Gemigliptin can be decreased when used in combination with Hydrochlorothiazide.Investigational
GitoformateThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Hydrochlorothiazide.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Hydrochlorothiazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydrochlorothiazide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
GlisoxepideThe therapeutic efficacy of Glisoxepide can be decreased when used in combination with Hydrochlorothiazide.Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Hydrochlorothiazide.Approved
GlycerinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Glycerin.Approved, Investigational
GlycodiazineThe therapeutic efficacy of Glycodiazine can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
GlycopyrroniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GosogliptinThe therapeutic efficacy of Gosogliptin can be decreased when used in combination with Hydrochlorothiazide.Investigational
GuacetisalThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Hydrochlorothiazide.Approved
GuanazodineHydrochlorothiazide may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineHydrochlorothiazide may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
GuanoclorHydrochlorothiazide may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzHydrochlorothiazide may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanHydrochlorothiazide may increase the hypotensive activities of Guanoxan.Experimental
Guar gumThe therapeutic efficacy of Guar gum can be decreased when used in combination with Hydrochlorothiazide.Experimental
HalcinonideHalcinonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational, Withdrawn
HalometasoneHalometasone may increase the hypokalemic activities of Hydrochlorothiazide.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Hydrochlorothiazide.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Hydrochlorothiazide.Experimental
HeptabarbitalThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Heptabarbital.Approved
HeroinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Hexamethonium.Experimental
HexobarbitalThe risk or severity of hypotension and orthostatic hypotension can be increased when Hexobarbital is combined with Hydrochlorothiazide.Approved
HexocycliumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Hexocyclium.Approved
HexoprenalineHexoprenaline may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Withdrawn
HomatropineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Homatropine.Approved
Homatropine MethylbromideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Homatropine Methylbromide.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Hydrochlorothiazide.Experimental
HydralazineHydralazine may increase the hypotensive activities of Hydrochlorothiazide.Approved
HydrocodoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Hydrocodone.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
Hydrocortisone aceponateHydrocortisone aceponate may increase the hypokalemic activities of Hydrochlorothiazide.Experimental, Vet Approved
Hydrocortisone acetateHydrocortisone acetate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
Hydrocortisone butyrateHydrocortisone butyrate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
Hydrocortisone probutateHydrocortisone probutate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
Hydrocortisone succinateHydrocortisone succinate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
Hydrocortisone valerateHydrocortisone valerate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
HydromorphoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Hydromorphone.Approved, Illicit
HyoscyamineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ibuproxam.Withdrawn
IcosapentThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Icosapent.Approved, Nutraceutical
IloprostIloprost may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
ImidafenacinThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Imidafenacin.Approved, Investigational
ImidaprilThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
IndalpineThe risk or severity of hyponatremia can be increased when Indalpine is combined with Hydrochlorothiazide.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Hydrochlorothiazide.Approved
IndenololHydrochlorothiazide may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
InecalcitolThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Inecalcitol.Experimental, Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Hydrochlorothiazide.Approved
Insulin BeefThe therapeutic efficacy of Insulin Beef can be decreased when used in combination with Hydrochlorothiazide.Approved
Insulin DegludecThe therapeutic efficacy of Insulin Degludec can be decreased when used in combination with Hydrochlorothiazide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Hydrochlorothiazide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydrochlorothiazide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Hydrochlorothiazide.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydrochlorothiazide.Approved
Insulin peglisproThe therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Hydrochlorothiazide.Investigational
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydrochlorothiazide.Approved
IpratropiumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Ipratropium.Approved
IproniazidIproniazid may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
IrbesartanHydrochlorothiazide may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Hydrochlorothiazide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Hydrochlorothiazide.Approved
IsofluraneThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Isoflurane.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
IsopropamideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Isopropamide.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Hydrochlorothiazide.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
IvabradineThe risk or severity of Cardiac Arrhythmia can be increased when Hydrochlorothiazide is combined with Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Hydrochlorothiazide.Investigational
KetobemidoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ketobemidone.Approved, Investigational
KetoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ketorolac.Approved
KRP-104The therapeutic efficacy of KRP-104 can be decreased when used in combination with Hydrochlorothiazide.Investigational
LabetalolLabetalol may increase the hypotensive activities of Hydrochlorothiazide.Approved
LacidipineHydrochlorothiazide may increase the hypotensive activities of Lacidipine.Approved, Investigational
LactitolThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Lactitol.Investigational
LactuloseThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Lactulose.Approved
LamotrigineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Lamotrigine.Approved, Investigational
Lanatoside CThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Lanatoside C.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Hydrochlorothiazide.Approved, Investigational
LevodopaHydrochlorothiazide may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Hydrochlorothiazide.Approved, Investigational
LevorphanolThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Levorphanol.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Hydrochlorothiazide.Approved, Investigational
LicoriceThe risk or severity of hypokalemia can be increased when Licorice is combined with Hydrochlorothiazide.Approved
LinaclotideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Linaclotide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydrochlorothiazide.Approved
LinezolidLinezolid may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
LinsidomineHydrochlorothiazide may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Hydrochlorothiazide.Approved
LisinoprilThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Lisinopril.Approved, Investigational
Lithium cationHydrochlorothiazide may decrease the excretion rate of Lithium cation which could result in a higher serum level.Experimental
LixisenatideThe therapeutic efficacy of Lixisenatide can be decreased when used in combination with Hydrochlorothiazide.Approved
LobeglitazoneThe therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
LofentanilThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Lofentanil.Illicit
LofexidineHydrochlorothiazide may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Lornoxicam.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Hydrochlorothiazide.Approved
LoteprednolLoteprednol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
LoxoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Loxoprofen.Approved, Investigational
LubiprostoneThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Lubiprostone.Approved, Investigational
LumiracoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanHydrochlorothiazide may increase the hypotensive activities of Macitentan.Approved
Magnesium carbonateThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Magnesium oxide.Approved
Magnesium peroxideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Magnesium peroxide.Experimental
Magnesium salicylateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineHydrochlorothiazide may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Mannitol.Approved, Investigational
MaprotilineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Maprotiline.Approved, Investigational
MaxacalcitolThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Maxacalcitol.Approved, Investigational
MazaticolThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Mazaticol.Experimental
MebanazineMebanazine may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
MebeverineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Mebeverine.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Mecamylamine.Approved, Investigational
MecaserminThe therapeutic efficacy of Mecasermin can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
Mefenamic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Hydrochlorothiazide.Vet Approved
MeloxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MepenzolateThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Mepenzolate.Approved
MeprednisoneMeprednisone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
MeptazinolThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Meptazinol.Experimental
MesalazineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mesalazine.Approved
MetahexamideThe therapeutic efficacy of Metahexamide can be decreased when used in combination with Hydrochlorothiazide.Experimental
MetamizoleThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Hydrochlorothiazide.Approved
MethadoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Methadone.Approved
Methadyl AcetateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Methadyl Acetate.Approved, Illicit
MethanthelineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Methantheline.Approved, Investigational
MetharbitalThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Metharbital.Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Hydrochlorothiazide.Approved
MethenamineThe risk or severity of adverse effects can be increased when Methenamine is combined with Hydrochlorothiazide.Approved, Vet Approved
MethohexitalThe risk or severity of hypotension and orthostatic hypotension can be increased when Methohexital is combined with Hydrochlorothiazide.Approved
MethoserpidineHydrochlorothiazide may increase the hypotensive activities of Methoserpidine.Experimental
MethotrexateThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Methotrexate.Approved
MethotrimeprazineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Methotrimeprazine.Approved, Investigational
MethscopolamineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Methscopolamine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Hydrochlorothiazide.Approved
Methyl celluloseThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Methyl cellulose.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Hydrochlorothiazide.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Hydrochlorothiazide.Approved, Investigational
MethylphenobarbitalThe risk or severity of hypotension and orthostatic hypotension can be increased when Methylphenobarbital is combined with Hydrochlorothiazide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
Methylscopolamine bromideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Methylscopolamine bromide.Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Metildigoxin.Experimental
MetipranololHydrochlorothiazide may increase the hypotensive activities of Metipranolol.Approved
MetixeneThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Metixene.Approved
MetocurineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Metocurine.Approved
Metocurine IodideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Metocurine Iodide.Approved, Withdrawn
MetolazoneMetolazone may increase the hypotensive activities of Hydrochlorothiazide.Approved
MetoprololMetoprolol may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
MetyrosineHydrochlorothiazide may increase the hypotensive activities of Metyrosine.Approved
MibefradilHydrochlorothiazide may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MifepristoneThe therapeutic efficacy of Mifepristone can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Hydrochlorothiazide.Approved
MilnacipranThe risk or severity of hyponatremia can be increased when Milnacipran is combined with Hydrochlorothiazide.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Hydrochlorothiazide.Approved
Mineral oilThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Mineral oil.Approved, Vet Approved
MinoxidilMinoxidil may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Hydrochlorothiazide.Investigational
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
MivacuriumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
MoexiprilThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
MometasoneMometasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
Mometasone furoateMometasone furoate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
MorniflumateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Morniflumate.Approved
MorphineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Morphine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
MuzolimineHydrochlorothiazide may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Hydrochlorothiazide.Approved, Investigational
NabumetoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nabumetone.Approved
NadololHydrochlorothiazide may increase the hypotensive activities of Nadolol.Approved
NaftopidilHydrochlorothiazide may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nalbuphine.Approved
NaltrexoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
NBI-6024The therapeutic efficacy of NBI-6024 can be decreased when used in combination with Hydrochlorothiazide.Investigational
NebivololHydrochlorothiazide may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of hyponatremia can be increased when Nefazodone is combined with Hydrochlorothiazide.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nepafenac.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nesiritide.Approved, Investigational
NetoglitazoneThe therapeutic efficacy of Netoglitazone can be decreased when used in combination with Hydrochlorothiazide.Experimental
NialamideNialamide may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
NicomorphineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nicomorphine.Experimental
NicorandilNicorandil may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nicotine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nifedipine.Approved
NifenazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineHydrochlorothiazide may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineHydrochlorothiazide may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Hydrochlorothiazide.Approved
NitrendipineHydrochlorothiazide may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Hydrochlorothiazide.Approved
NitroaspirinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Hydrochlorothiazide.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Hydrochlorothiazide.Approved, Investigational
NN344The therapeutic efficacy of NN344 can be decreased when used in combination with Hydrochlorothiazide.Investigational
NorepinephrineNorepinephrine may increase the hypokalemic activities of Hydrochlorothiazide.Approved
NormethadoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Normethadone.Approved, Illicit
NortriptylineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Nortriptyline.Approved
NS-398The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with NS-398.Experimental
ObinutuzumabHydrochlorothiazide may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
OlanzapineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Olanzapine.Approved, Investigational
OleandrinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Oleandrin.Experimental, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
OlsalazineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Omapatrilat.Investigational
OmarigliptinThe therapeutic efficacy of Omarigliptin can be decreased when used in combination with Hydrochlorothiazide.Investigational
OpiumThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Opium.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Hydrochlorothiazide.Approved
OrphenadrineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Orphenadrine.Approved
OtiloniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Otilonium.Experimental, Investigational
OuabainThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of hyponatremia can be increased when Hydrochlorothiazide is combined with Oxcarbazepine.Approved
OxitropiumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Oxitropium.Investigational
OxprenololHydrochlorothiazide may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
OxyphencyclimineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Oxyphencyclimine.Approved
OxyphenisatinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Oxyphenisatin.Investigational, Withdrawn
OxyphenoniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Oxyphenonium.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hydrochlorothiazide.Approved, Vet Approved
PancuroniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Papaverine.Approved, Investigational
ParamethasoneParamethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
ParecoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Hydrochlorothiazide.Approved
ParicalcitolThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Paricalcitol.Approved, Investigational
ParoxetineThe risk or severity of hyponatremia can be increased when Paroxetine is combined with Hydrochlorothiazide.Approved, Investigational
PenbutololHydrochlorothiazide may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentaerithritylThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Pentaerithrityl.Experimental
PentamidineThe therapeutic efficacy of Pentamidine can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
PentazocineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Pentazocine.Approved, Vet Approved
PenthienateThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Penthienate.Experimental
PentobarbitalThe risk or severity of hypotension and orthostatic hypotension can be increased when Pentobarbital is combined with Hydrochlorothiazide.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Pentolinium.Approved
PerindoprilThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Perindopril.Approved
PerindoprilatThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Perindoprilat.Experimental
PeruvosideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Peruvoside.Experimental
PethidineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Pethidine.Approved
PF-00610355PF-00610355 may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
PhenazocineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Hydrochlorothiazide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational, Withdrawn
PhenglutarimideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Phenglutarimide.Experimental
PhenindioneThe therapeutic efficacy of Phenindione can be increased when used in combination with Hydrochlorothiazide.Approved, Investigational
PheniprazinePheniprazine may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
PhenobarbitalThe risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Hydrochlorothiazide.Approved, Investigational
PhenolphthaleinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Phenolphthalein.Approved, Withdrawn
PhenoperidineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Hydrochlorothiazide.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
PhenprocoumonThe therapeutic efficacy of Phenprocoumon can be increased when used in combination with Hydrochlorothiazide.Approved, Investigational
PhentolaminePhentolamine may increase the hypotensive activities of Hydrochlorothiazide.Approved
PhenylbutazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved, Withdrawn
Picosulfuric acidThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Picosulfuric acid.Approved
PinacidilPinacidil may increase the hypotensive activities of Hydrochlorothiazide.Approved
PindololHydrochlorothiazide may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Hydrochlorothiazide.Approved, Investigational
PipecuroniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pipecuronium.Approved
PipenzolateThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pipenzolate.Experimental
PiperidolateThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Piperidolate.Experimental
PirbuterolPirbuterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
PirenzepineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pirenzepine.Approved
PiritramideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Piritramide.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Hydrochlorothiazide.Approved
PiroxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
PizotifenThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pizotifen.Approved
Plantago seedThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Plantago seed.Approved, Investigational
PlecanatideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Plecanatide.Approved, Investigational
PoldineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Poldine.Experimental
PolycarbophilThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Polycarbophil.Approved
Polyethylene glycolThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Polyethylene glycol.Approved, Vet Approved
PolythiazideHydrochlorothiazide may increase the hypotensive activities of Polythiazide.Approved
Potassium acetateThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Potassium acetate.Approved, Investigational
PractololHydrochlorothiazide may increase the hypotensive activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Hydrochlorothiazide.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
PranoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Hydrochlorothiazide.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
PrednisolonePrednisolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
PrednylidenePrednylidene may increase the hypokalemic activities of Hydrochlorothiazide.Experimental
PrifiniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Prifinium.Experimental
PrimidoneThe risk or severity of hypotension and orthostatic hypotension can be increased when Primidone is combined with Hydrochlorothiazide.Approved, Vet Approved
ProcaineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Procaine.Approved, Investigational, Vet Approved
ProcaterolProcaterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
ProcyclidineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Procyclidine.Approved
ProglumetacinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Proglumetacin.Experimental
PromazineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Promethazine.Approved, Investigational
PropacetamolThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Propacetamol.Approved, Investigational
PropanthelineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Propantheline.Approved
PropiomazineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Propiomazine.Approved
PropiverineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Hydrochlorothiazide.Approved, Investigational, Vet Approved
PropranololHydrochlorothiazide may increase the hypotensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Proscillaridin.Experimental
ProtokylolProtokylol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
PrucaloprideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Prucalopride.Approved
QuetiapineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Quetiapine.Approved
QuinaprilThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Quinapril.Approved, Investigational
QuinaprilatThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Quinaprilat.Experimental
QuinidineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe therapeutic efficacy of Quinine can be decreased when used in combination with Hydrochlorothiazide.Approved
RacepinephrineRacepinephrine may increase the hypokalemic activities of Hydrochlorothiazide.Approved
RamiprilThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Ramipril.Approved
RamiprilatThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Ramiprilat.Experimental
RapacuroniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Hydrochlorothiazide.Approved
RemifentanilThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Hydrochlorothiazide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
RescinnamineThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
RevefenacinThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Revefenacin.Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
RiociguatHydrochlorothiazide may increase the hypotensive activities of Riociguat.Approved
RisperidoneHydrochlorothiazide may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of hyponatremia can be increased when Ritanserin is combined with Hydrochlorothiazide.Investigational
RitodrineRitodrine may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
RituximabHydrochlorothiazide may increase the hypotensive activities of Rituximab.Approved
RivoglitazoneThe therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Hydrochlorothiazide.Experimental, Investigational
RobenacoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Robenacoxib.Experimental, Vet Approved
RociverineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Rociverine.Experimental
RocuroniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Rocuronium.Approved
RofecoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Hydrochlorothiazide.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Hydrochlorothiazide.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Hydrochlorothiazide.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Hydrochlorothiazide.Approved
SafinamideSafinamide may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
SalsalateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salsalate.Approved
SaprisartanHydrochlorothiazide may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Hydrochlorothiazide.Approved
SC-236The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with SC-236.Experimental, Investigational
ScopolamineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of hypotension and orthostatic hypotension can be increased when Secobarbital is combined with Hydrochlorothiazide.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational, Vet Approved
SelexipagHydrochlorothiazide may increase the hypotensive activities of Selexipag.Approved
SemaglutideThe therapeutic efficacy of Semaglutide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
SennosidesThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Sennosides.Approved
SeocalcitolThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Seocalcitol.Experimental, Investigational
SertralineThe risk or severity of hyponatremia can be increased when Sertraline is combined with Hydrochlorothiazide.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Hydrochlorothiazide.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Hydrochlorothiazide.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
SitaxentanHydrochlorothiazide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphate, monobasicHydrochlorothiazide may increase the nephrotoxic activities of Sodium phosphate, monobasic.Approved
Sodium sulfateThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Sodium sulfate.Approved, Vet Approved
Sodium tartrateThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Sodium tartrate.Approved
SolifenacinThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Solifenacin.Approved
SorbitolThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Sorbitol.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Hydrochlorothiazide.Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Hydrochlorothiazide.Approved
SpiraprilThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Hydrochlorothiazide.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Hydrochlorothiazide.Approved, Investigational
SufentanilThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Sufentanil.Approved, Investigational
SulfadiazineThe therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational, Vet Approved
SulfamethoxazoleThe therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Hydrochlorothiazide.Approved
SulfasalazineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Sulfasalazine.Approved
SulfisoxazoleThe therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
SulindacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Sulindac.Approved, Investigational
SulpirideThe risk or severity of orthostatic hypotension can be increased when Hydrochlorothiazide is combined with Sulpiride.Approved, Investigational
SunitinibThe therapeutic efficacy of Sunitinib can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
SuprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Suxibuzone.Experimental
TacalcitolThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Tacalcitol.Experimental, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Hydrochlorothiazide.Approved, Investigational
TalbutalThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Talbutal.Approved, Illicit
TalinololHydrochlorothiazide may increase the hypotensive activities of Talinolol.Investigational
TalniflumateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Talniflumate.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Hydrochlorothiazide.Approved, Investigational
TapentadolThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tapentadol.Approved
TaspoglutideThe therapeutic efficacy of Taspoglutide can be decreased when used in combination with Hydrochlorothiazide.Investigational
TegaserodThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Tegaserod.Approved, Investigational, Withdrawn
TelmisartanTelmisartan may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
TemocaprilThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Temocapril.Experimental, Investigational
TeneligliptinThe therapeutic efficacy of Teneligliptin can be decreased when used in combination with Hydrochlorothiazide.Investigational
TenidapThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinHydrochlorothiazide may increase the hypotensive activities of Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Hydrochlorothiazide.Approved
TerfenadineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Terfenadine.Approved, Withdrawn
TetraethylammoniumThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Tetraethylammonium.Experimental, Investigational
TetrahydropalmatineHydrochlorothiazide may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Hydrochlorothiazide.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the antihypertensive activities of Hydrochlorothiazide.Approved
ThiamylalThe risk or severity of hypotension and orthostatic hypotension can be increased when Thiamylal is combined with Hydrochlorothiazide.Approved, Vet Approved
ThiopentalThe risk or severity of hypotension and orthostatic hypotension can be increased when Thiopental is combined with Hydrochlorothiazide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Hydrochlorothiazide.Approved, Withdrawn
ThonzylamineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Thonzylamine.Approved
Tiaprofenic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tiaprofenic acid.Approved
TicrynafenHydrochlorothiazide may increase the hypotensive activities of Ticrynafen.Withdrawn
Tiemonium iodideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tiemonium iodide.Experimental
TilidineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tilidine.Experimental
TimepidiumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Timepidium.Experimental
TimololHydrochlorothiazide may increase the hypotensive activities of Timolol.Approved
TinoridineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tinoridine.Investigational
TioclomarolThe therapeutic efficacy of Tioclomarol can be increased when used in combination with Hydrochlorothiazide.Experimental
TiotropiumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Withdrawn
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Hydrochlorothiazide.Approved, Investigational
TocopherylquinoneHydrochlorothiazide may increase the hypotensive activities of Tocopherylquinone.Experimental, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Hydrochlorothiazide.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tolmetin.Approved
TolonidineHydrochlorothiazide may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Hydrochlorothiazide.Approved
TolterodineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of hypokalemia can be increased when Hydrochlorothiazide is combined with Topiramate.Approved
TorasemideTorasemide may increase the hypotensive activities of Hydrochlorothiazide.Approved
ToremifeneThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Toremifene.Approved, Investigational
TramadolThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tramadol.Approved, Investigational
TrandolaprilThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Hydrochlorothiazide.Approved
TrazodoneThe risk or severity of hyponatremia can be increased when Trazodone is combined with Hydrochlorothiazide.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Hydrochlorothiazide.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Hydrochlorothiazide.Approved
TrichlormethiazideHydrochlorothiazide may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TridihexethylThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tridihexethyl.Withdrawn
TriflupromazineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Trihexyphenidyl.Approved
TrilostaneTrilostane may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational, Vet Approved, Withdrawn
TrimazosinTrimazosin may increase the hypotensive activities of Hydrochlorothiazide.Experimental
TrimebutineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Trimebutine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Trimethaphan.Approved, Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Hydrochlorothiazide.Investigational, Withdrawn
Trolamine salicylateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Trolamine salicylate.Approved
TropatepineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tropatepine.Experimental
TropicamideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tropicamide.Approved, Investigational
TrospiumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Trospium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Hydrochlorothiazide.Approved, Investigational
UlobetasolUlobetasol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
UmeclidiniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Umeclidinium.Approved
UnoprostoneHydrochlorothiazide may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Hydrochlorothiazide.Investigational
ValdecoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanHydrochlorothiazide may increase the hypotensive activities of Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Hydrochlorothiazide.Approved
VecuroniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Vecuronium.Approved
VenlafaxineThe risk or severity of hyponatremia can be increased when Venlafaxine is combined with Hydrochlorothiazide.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Hydrochlorothiazide.Approved
VilanterolVilanterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
VincamineHydrochlorothiazide may increase the hypotensive activities of Vincamine.Experimental
Vitamin DThe risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Vitamin D.Approved, Nutraceutical, Vet Approved
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
WarfarinThe therapeutic efficacy of Warfarin can be increased when used in combination with Hydrochlorothiazide.Approved
XipamideHydrochlorothiazide may increase the hypotensive activities of Xipamide.Experimental
YohimbineYohimbine may decrease the antihypertensive activities of Hydrochlorothiazide.Approved, Investigational, Vet Approved
ZaltoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZimelidineThe risk or severity of hyponatremia can be increased when Zimelidine is combined with Hydrochlorothiazide.Withdrawn
ZiprasidoneThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Avoid excess salt/sodium unless otherwise instructed by your physician.
  • Avoid natural licorice.
  • Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.
  • Increase potassium intake; add a banana or orange juice; unless instructed otherwise.
  • Take with food.

References

Synthesis Reference

Frederic J. Nugent, John K. C. Yen, "Process for preparing the combination products of triamterene and hydrochlorothiazide." U.S. Patent US4804540, issued July, 1987.

US4804540
General References
  1. Significant Drug–Drug Interactions with Antineoplastics [Link]
  2. Thiazide-Induced Vasodilation in Humans Is Mediated by Potassium Channel Activation [File]
External Links
Human Metabolome Database
HMDB0001928
KEGG Drug
D00340
KEGG Compound
C07041
PubChem Compound
3639
PubChem Substance
46504440
ChemSpider
3513
BindingDB
13076
ChEBI
5778
ChEMBL
CHEMBL435
Therapeutic Targets Database
DAP000750
PharmGKB
PA449899
HET
HCZ
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Hydrochlorothiazide
ATC Codes
C09XA52 — Aliskiren and hydrochlorothiazideC09DX03 — Olmesartan medoxomil, amlodipine and hydrochlorothiazideC03AB03 — Hydrochlorothiazide and potassiumC09DX01 — Valsartan, amlodipine and hydrochlorothiazideC03EA01 — Hydrochlorothiazide and potassium-sparing agentsC03AX01 — Hydrochlorothiazide, combinationsG01AE10 — Combinations of sulfonamidesC09XA54 — Aliskiren, amlodipine and hydrochlorothiazideC03AA03 — Hydrochlorothiazide
AHFS Codes
  • 40:28.20 — Thiazide Diuretics
PDB Entries
3ijx / 3ik6
MSDS
Download (72.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedNot AvailableHealthy Volunteers1
0TerminatedHealth Services ResearchHigh Blood Pressure (Hypertension) / Proteinuria / Type 2 Diabetes Mellitus1
1CompletedNot AvailableHealthy Volunteers10
1CompletedNot AvailableHypertension,Essential2
1CompletedNot AvailableKidney Diseases1
1CompletedTreatmentFasting1
1CompletedTreatmentHealthy Volunteers12
1CompletedTreatmentHigh Blood Pressure (Hypertension)5
1CompletedTreatmentType 2 Diabetes Mellitus3
1Unknown StatusTreatmentHealthy Volunteers1
1, 2RecruitingBasic ScienceHypertension,Essential1
2CompletedBasic ScienceType 2 Diabetes Mellitus1
2CompletedTreatmentAging / Cognitive Impairments / High Blood Pressure (Hypertension)1
2CompletedTreatmentBMI >30 kg/m2 / High Blood Pressure (Hypertension)1
2CompletedTreatmentHigh Blood Pressure (Hypertension)3
2CompletedTreatmentHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
2CompletedTreatmentHypertension,Essential1
2CompletedTreatmentMild Hypertension1
2RecruitingPreventionAging / High Blood Pressure (Hypertension) / Sedentary Lifestyle1
2RecruitingTreatmentAutosomal Dominant Hypocalcemia / Autosomal Dominant Hypocalcemia or OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment1
2RecruitingTreatmentBMI >30 kg/m2 / High Blood Pressure (Hypertension) / Prehypertension1
2RecruitingTreatmentHigh Blood Pressure (Hypertension)1
2TerminatedTreatmentHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
2TerminatedTreatmentNon-diabetic Nephropathy1
2TerminatedTreatmentPre-Diabetic / Pre-Hypertension1
2WithdrawnTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
2, 3CompletedTreatmentGrade I or II Essential Hypertension1
2, 3TerminatedTreatmentCalcium Nephrolithiasis / Dent's Disease1
3CompletedNot AvailableCardiovascular Disease (CVD) / Death, Sudden,Cardiac / Heart Arrest / Heart Diseases / High Blood Pressure (Hypertension)1
3CompletedDiagnosticHigh Blood Pressure (Hypertension)1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
3CompletedTreatmentAtherosclerotic Cardiovascular Diseases / Hypertension,Essential1
3CompletedTreatmentChronic Kidney Disease (CKD) / High Blood Pressure (Hypertension)1
3CompletedTreatmentHigh Blood Pressure (Hypertension)35
3CompletedTreatmentHigh Blood Pressure (Hypertension) / Metabolic Disorders1
3CompletedTreatmentHigh Blood Pressure (Hypertension) / Obesity, Abdominal1
3CompletedTreatmentHypertension,Essential11
3CompletedTreatmentHypertension; Hypertrophy, Left Ventricular1
3CompletedTreatmentSafety1
3Not Yet RecruitingTreatmentArterial Hypertension1
3Not Yet RecruitingTreatmentEssential Arterial Hypertension1
3Not Yet RecruitingTreatmentHigh Blood Pressure (Hypertension)2
3RecruitingPreventionCalcium Nephrolithiasis1
3RecruitingPreventionGestational Hypertension / Hypertension, Pregnancy-Induced / Postpartum Preeclampsia / Postpartum Pregnancy-Induced Hypertension / Prophylaxis of preeclampsia / Superimposed Pre-Eclampsia1
3RecruitingTreatmentHigh Blood Pressure (Hypertension)1
3TerminatedTreatmentCardiovascular Events1
3WithdrawnTreatmentEssential Arterial Hypertension2
4Active Not RecruitingTreatmentObstructive Sleep Apnea (OSA)1
4CompletedDiagnosticHigh Blood Pressure (Hypertension)2
4CompletedDiagnosticHypertension,Essential1
4CompletedPreventionNonvalvular Atrial Fibrillation1
4CompletedTreatmentAlbuminuria / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
4CompletedTreatmentBMI >30 kg/m2 / High Blood Pressure (Hypertension)1
4CompletedTreatmentChronic Kidney Disease (CKD)1
4CompletedTreatmentCoronary Artery Disease / High Blood Pressure (Hypertension)1
4CompletedTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
4CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
4CompletedTreatmentEssential Hypertension ( Mild to Moderate)1
4CompletedTreatmentHigh Blood Pressure (Hypertension)34
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Impaired Renal Function1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Left Ventricle Hypertrophy1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Metabolic Syndromes2
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Metabolic Syndromes / Obesity, Abdominal1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Pharmacogenetics1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus3
4CompletedTreatmentHypertension, Dyslypidaemia1
4CompletedTreatmentHypokalaemia1
4CompletedTreatmentStage 2 Systolic Hypertension1
4CompletedTreatmentStage II Hypertension1
4Not Yet RecruitingTreatmentBlood Pressures / Cardiovascular Risk Factors / Prehypertension / Strokes / Type 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentChronic Kidney Disease (CKD)1
4Not Yet RecruitingTreatmentHigh Blood Pressure (Hypertension)1
4Not Yet RecruitingTreatmentHypertension,Essential1
4Not Yet RecruitingTreatmentType 2 Diabetes Mellitus1
4RecruitingBasic ScienceFeeling Anxious / High Blood Pressure (Hypertension)1
4RecruitingPreventionBlood Pressures / High Blood Pressure (Hypertension) / Strokes1
4RecruitingTreatmentCerebral Small Vessels Disease1
4RecruitingTreatmentChronic Kidney Disease (CKD)1
4RecruitingTreatmentHeart Failure, Unspecified1
4RecruitingTreatmentHigh Blood Pressure (Hypertension)3
4RecruitingTreatmentPediatric Hypertension1
4RecruitingTreatmentType 2 Diabetes Mellitus1
4SuspendedTreatmentEnd Stage Renal Disease (ESRD) / High Blood Pressure (Hypertension) / Proteinuria1
4Unknown StatusPreventionDiabetic Nephropathies1
4Unknown StatusTreatmentBlood Pressures1
4Unknown StatusTreatmentDiuresis Preserved / Hemodialysis Treatment / Kidney Insufficiency, Chronic1
4Unknown StatusTreatmentHigh Blood Pressure (Hypertension)4
4Unknown StatusTreatmentHypertension, Resistant to Conventional Therapy / Hypertension,Essential1
4Unknown StatusTreatmentLipotoxicity / Metabolic Syndromes1
4WithdrawnTreatmentHigh Blood Pressure (Hypertension)3
4WithdrawnTreatmentHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableAging / High Blood Pressure (Hypertension)1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / High Blood Pressure (Hypertension) / Myocardial Infarction1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Heart Diseases / High Blood Pressure (Hypertension)1
Not AvailableCompletedNot AvailableHealthy Normotensive Participants3
Not AvailableCompletedNot AvailableHealthy Volunteers4
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension)9
Not AvailableCompletedNot AvailableHypertension,Essential1
Not AvailableCompletedDiagnosticArterial Hypertension1
Not AvailableCompletedDiagnosticGitelman's syndrome1
Not AvailableCompletedDiagnosticHigh Blood Pressure (Hypertension)1
Not AvailableCompletedTreatmentAlbuminuria / Diabetes Mellitus (DM) / Endothelial Dysfunction1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension)8
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension) / Hypertension Treatment / Hypertension, Grade 1 / N of 1 Study Design1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension) / Plasma Renin Activity1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentHypertension,Essential1
Not AvailableCompletedTreatmentNephrogenic Diabetes Insipidus1
Not AvailableCompletedTreatmentNocturia1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus / Vascular Diseases1
Not AvailableRecruitingNot AvailableHypertension,Essential1
Not AvailableRecruitingPreventionChronic Kidney Disease (CKD) / Hyperparathyroidism, Secondary1
Not AvailableRecruitingPreventionRenal Stones1
Not AvailableRecruitingTreatmentCritical Care / Fluid Shifts1
Not AvailableTerminatedPreventionMetabolic Syndromes1
Not AvailableTerminatedTreatmentHigh Blood Pressure (Hypertension) / Microvascular Angina1
Not AvailableUnknown StatusNot AvailableArterial Hypertension / Diabetes Mellitus (DM)1

Pharmacoeconomics

Manufacturers
  • Apotex inc
  • Aurobindo pharma ltd
  • Cadista pharmaceuticals inc
  • Ipca laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Unichem laboratories ltd
  • Vintage pharmaceuticals inc
  • West ward pharmaceutical corp
  • Watson laboratories inc
  • Morton grove pharmaceuticals inc
  • Roxane laboratories inc
  • Novartis pharmaceuticals corp
  • Abc holding corp
  • Actavis elizabeth llc
  • Alra laboratories inc
  • Ascot hosp pharmaceuticals inc div travenol laboratories inc
  • Barr laboratories inc
  • Caraco pharmaceutical laboratories ltd
  • Dava pharmaceuticals inc
  • Elkins sinn div ah robins co inc
  • Excellium pharmaceutical inc
  • Heather drug co inc
  • Heritage pharmaceuticals inc
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Lannett holdings inc
  • Mm mast and co
  • Mutual pharmaceutical co inc
  • Private formulations inc
  • Sandoz inc
  • Solvay pharmaceuticals
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Tg united labs llc
  • Usl pharma inc
  • Vangard laboratories inc div midway medical co
  • Warner chilcott div warner lambert co
  • Whiteworth towne paulsen inc
  • Halsey drug co inc
  • Merck and co inc
  • Abbott laboratories pharmaceutical products div
Packagers
  • Abbott Laboratories Ltd.
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • Aidarex Pharmacuticals LLC
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • AstraZeneca Inc.
  • Atlantic Biologicals Corporation
  • Aurobindo Pharma Ltd.
  • Barr Pharmaceuticals
  • Boehringer Ingelheim Ltd.
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • BTA Pharmaceuticals
  • C.O. Truxton Inc.
  • Cadista Pharmaceuticals Inc.
  • Calvin Scott and Co. Inc.
  • Caraco Pharmaceutical Labs
  • Cardinal Health
  • Carlisle Laboratories Inc.
  • Central Texas Community Health Centers
  • Ciba Geigy Ltd.
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Coupler Enterprises Inc.
  • Darby Dental Supply Co. Inc.
  • DAVA Pharmaceuticals
  • Dee Stevens and Son Feeder
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • Duramed
  • E.R. Squibb and Sons LLC
  • Endo Pharmaceuticals Inc.
  • Eon Labs
  • Excellium Pharmaceutical Inc.
  • Genpharm LP
  • Glenmark Generics Ltd.
  • Golden State Medical Supply Inc.
  • Goldline Laboratories Inc.
  • Greenstone LLC
  • Group Health Cooperative
  • H and H Laboratories
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Heritage Pharmaceuticals
  • International Laboratories Inc.
  • Ipca Laboratories Ltd.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Kraft Pharmaceutical Co. Inc.
  • Lake Erie Medical and Surgical Supply
  • Lannett Co. Inc.
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medisca Inc.
  • Medvantx Inc.
  • Merck & Co.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • Ohm Laboratories Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • Patheon Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Pharmpak Inc.
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Qualitest
  • Quality Research Pharmaceutical Inc.
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Roxane Labs
  • Sandoz
  • Solvay Pharmaceuticals
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Stat Scripts LLC
  • Talbert Medical Management Corp.
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Unichem Laboratories Ltd.
  • United Research Laboratories Inc.
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Vintage Pharmaceuticals Inc.
  • Watson Pharmaceuticals
  • West-Ward Pharmaceuticals
Dosage forms
FormRouteStrength
Tablet, film coatedOral
TabletOral50 mg
TabletOral12.5 mg
Tablet, coatedOral
CapsuleOral12.5 mg/1
Capsule, gelatin coatedOral12.5 mg/1
TabletOral12.5 mg/1
TabletOral25 mg/25mg
TabletOral25 mg/1
TabletOral50 mg/1
TabletOral50 mg/50mg
TabletOral25 mg
TabletOral100 mg
TabletOral
CapsuleOral
Prices
Unit descriptionCostUnit
Niferex-150 Forte 100 80-70 mg capsule Box109.86USD box
Niferex 100 mg/5ml Elixir 236ml Bottle80.55USD bottle
Niferex 100 40-20 mg capsule Box77.99USD box
Capozide 50-25 mg tablet3.63USD tablet
Ziac 10-6.25 mg tablet3.6USD tablet
Ziac 2.5-6.25 mg tablet3.6USD tablet
Ziac 5-6.25 mg tablet3.6USD tablet
Capozide 50-15 tablet3.49USD tablet
Capozide 50-25 tablet3.49USD tablet
Capozide 50-15 mg tablet2.59USD tablet
Lotensin 20 mg tablet2.25USD tablet
Lotensin 10 mg tablet2.09USD tablet
Lotensin 40 mg tablet2.09USD tablet
Lotensin 5 mg tablet2.09USD tablet
Accuretic 20-12.5 mg tablet2.04USD tablet
Capozide 25-15 tablet2.03USD tablet
Capozide 25-25 tablet2.03USD tablet
Accuretic 10-12.5 mg tablet2.0USD tablet
Accuretic 20-25 mg tablet2.0USD tablet
Lotensin HCT 20-12.5 mg tablet1.97USD tablet
Lotensin HCT 10-12.5 mg tablet1.95USD tablet
Lotensin HCT 20-25 mg tablet1.94USD tablet
Lotensin hct 10-12.5 tablet1.9USD tablet
Lotensin hct 20-12.5 tablet1.9USD tablet
Lotensin hct 20-25 tablet1.9USD tablet
Lotensin hct 5-6.25 tablet1.9USD tablet
Niferex-150 150-50-50 mg capsule1.62USD capsule
Capozide 25-15 mg tablet1.51USD tablet
Lotensin HCT 5-6.25 mg tablet1.31USD tablet
Hydrochlorothiazide powder1.1USD g
Hydrochlorothiazide 12.5 mg tablet0.82USD tablet
Moduretic 5-50 mg tablet0.68USD tablet
Hydrochlorothiazide 12.5 mg capsule0.5USD capsule
Hydrochlorothiazide 50 mg tablet0.16USD tablet
Apo-Hydro 100 mg Tablet0.13USD tablet
Hydrochlorothiazide 25 mg tablet0.11USD tablet
Apo-Hydro 50 mg Tablet0.06USD tablet
Novo-Hydrazide 50 mg Tablet0.06USD tablet
Apo-Hydro 25 mg Tablet0.04USD tablet
Novo-Hydrazide 25 mg Tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6294197Yes1997-12-182017-12-18Us
US6358986No2000-01-102020-01-10Us
US5559111Yes1999-01-212019-01-21Us
US5616599Yes1996-10-252016-10-25Us
US8618172No2008-07-132028-07-13Us
US6878703Yes2002-05-192022-05-19Us
US8101599No2003-05-162023-05-16Us
US8475839Yes2003-11-162023-11-16Us
US8618174No2001-11-152021-11-15Us
US8183295No2003-05-162023-05-16Us
US5994348Yes1995-12-072015-12-07Us
US9023893No2002-03-032022-03-03Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)266-268U.S. Patent 3,163,645.
water solubility722 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-0.07HANSCH,C ET AL. (1995)
logS-2.62ADME Research, USCD
Caco2 permeability-6.06ADME Research, USCD
pKa7.9SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility2.24 mg/mLALOGPS
logP-0.16ALOGPS
logP-0.58ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)9.09ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.36 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity63.11 m3·mol-1ChemAxon
Polarizability25.35 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9202
Blood Brain Barrier-0.9659
Caco-2 permeable-0.8956
P-glycoprotein substrateNon-substrate0.6533
P-glycoprotein inhibitor INon-inhibitor0.8624
P-glycoprotein inhibitor IINon-inhibitor0.8688
Renal organic cation transporterNon-inhibitor0.8416
CYP450 2C9 substrateNon-substrate0.7664
CYP450 2D6 substrateNon-substrate0.8333
CYP450 3A4 substrateNon-substrate0.6217
CYP450 1A2 substrateNon-inhibitor0.9401
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9252
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9569
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9036
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7986
BiodegradationNot ready biodegradable0.9964
Rat acute toxicity2.0666 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9576
hERG inhibition (predictor II)Non-inhibitor0.9135
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (11.5 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-00r2-6490000000-3f5d9320308b823c6489
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-052b-0090000000-aaa48e4702874457ae26
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-0r6r-0920000000-b129acf72e7dde12441e
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-0a4i-1900000000-67f803f38aed0bd12ade
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0090000000-7906a6e4cfb51dce1396
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0090000000-c44dbed5084dc5df03d8
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0090000000-976dcb246a2272b22565
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0uxr-1090000000-16e563e592e4a566424d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0fb9-9580000000-3c9227e3df8ed6dc9ae9
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9720000000-12525bfcb83ea1611970
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9200000000-df37b796b59f084b0229
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0090000000-220666bc28231ad387e8
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0002-0090000000-f434c5d8ee94540ec0d2
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0uxr-1090000000-8a3c270e0fb285b26f15
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0fb9-9480000000-5f6c5ed1d291d71a0aae
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9520000000-679def33e8239c1382f3
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-9400000000-c9b80274d62fda64c531
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0090000000-0a962453b9e31eec3822
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0002-0090000000-ac2b5d07eaacba87a181
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0gb9-1090000000-8649018477d708cb6bd7
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-004i-9400000000-266cd4efe3deeebe29f3
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-014i-0090000000-bc85dd2515151e4fec03
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0090000000-f8a0765b6023cbf47593
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0090000000-ca679180c1ca0c54141e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0090000000-5aee0df6931c521ae675
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0390000000-2d94b79cdd59fb180851
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f79-0920000000-a3852b5fd8f817191c39
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-017f1f0aa88d206d3790
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05br-1900000000-9adb8f34fa45627894bb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0090000000-49e6e4b4d7de4164fea3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0090000000-eba848023908f7d51e1a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0490000000-09360a196ae79b28c238
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f79-0920000000-f620823c599998180372
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-1900000000-bb4b565d2cab86e56d75
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-052r-2900000000-67c9a5ba10fd79140b7d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0090000000-de56ae9572cecd0e3bce
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-00lr-0090000000-6ec2b0c4b0ea116fd154
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0490000000-86abfe4bae6e32f1189a
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,2,4-benzothiadiazine-1,1-dioxides. These are aromatic heterocyclic compounds containing a 1,2,4-benzothiadiazine ring system with two S=O bonds at the 1-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Thiadiazines
Sub Class
Benzothiadiazines
Direct Parent
1,2,4-benzothiadiazine-1,1-dioxides
Alternative Parents
Secondary alkylarylamines / Organosulfonamides / Benzenoids / Aryl chlorides / Aminosulfonyl compounds / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives
Substituents
1,2,4-benzothiadiazine-1,1-dioxide / Secondary aliphatic/aromatic amine / Aryl chloride / Aryl halide / Organosulfonic acid amide / Benzenoid / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Aminosulfonyl compound / Sulfonyl
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
sulfonamide, organochlorine compound, benzothiadiazine (CHEBI:5778)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
Gene Name
SLC12A3
Uniprot ID
P55017
Uniprot Name
Solute carrier family 12 member 3
Molecular Weight
113138.04 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Ran XW, Wang C, Dai F, Jiang JJ, Tong NW, Li XJ, Liang JZ: [A case of Gitelman's syndrome presenting with severe hypocalcaemia and hypokalemic periodic paralysis]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 Jul;36(4):583-7. [PubMed:16078592]
  3. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E: WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension. 2005 Oct;46(4):758-65. Epub 2005 Sep 19. [PubMed:16172412]
  4. Abuladze N, Yanagawa N, Lee I, Jo OD, Newman D, Hwang J, Uyemura K, Pushkin A, Modlin RL, Kurtz I: Peripheral blood mononuclear cells express mutated NCCT mRNA in Gitelman's syndrome: evidence for abnormal thiazide-sensitive NaCl cotransport. J Am Soc Nephrol. 1998 May;9(5):819-26. [PubMed:9596079]
  5. Barry EL, Gesek FA, Kaplan MR, Hebert SC, Friedman PA: Expression of the sodium-chloride cotransporter in osteoblast-like cells: effect of thiazide diuretics. Am J Physiol. 1997 Jan;272(1 Pt 1):C109-16. [PubMed:9038817]
  6. Kurschat C, Heering P, Grabensee B: [Gitelman's syndrome: an important differential diagnosis of hypokalemia]. Dtsch Med Wochenschr. 2003 May 30;128(22):1225-8. [PubMed:12772080]
  7. Monroy A, Plata C, Hebert SC, Gamba G: Characterization of the thiazide-sensitive Na(+)-Cl(-) cotransporter: a new model for ions and diuretics interaction. Am J Physiol Renal Physiol. 2000 Jul;279(1):F161-9. [PubMed:10894798]
  8. Significant Drug–Drug Interactions with Antineoplastics [Link]
Details
2. Carbonic anhydrase 1
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name
CA1
Uniprot ID
P00915
Uniprot Name
Carbonic anhydrase 1
Molecular Weight
28870.0 Da
References
  1. Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865]
Details
3. Carbonic anhydrase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. Schaeffer P, Vigne P, Frelin C, Lazdunski M: Identification and pharmacological properties of binding sites for the atypical thiazide diuretic, indapamide. Eur J Pharmacol. 1990 Jul 17;182(3):503-8. [PubMed:2226620]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activati...
Gene Name
KCNMA1
Uniprot ID
Q12791
Uniprot Name
Calcium-activated potassium channel subunit alpha-1
Molecular Weight
137558.115 Da
References
  1. Thiazide-Induced Vasodilation in Humans Is Mediated by Potassium Channel Activation [File]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [PubMed:10049739]
  2. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:47